He apelin receptor, APJ, is a G-protein–coupled receptor that was discovered in 1993 based on its homology to the angiotensin II type 1 receptor. The endogenous APJ ligands were identified 5 years later and are a group of peptides referred to as apelins that are all derived from a single prepeptide. The apelins vary in length and in their ability to induce APJ signaling and trafficking but are often treated as a single entity, with apelin referring to the most potent 13-amino-acid fragment. Canonical apelin-stimulated APJ signaling involves activation of pertussis toxin-sensitive G-proteins (G, or G) leading to reduced cAMP production, as well as the activation of phospholipase C, protein kinase C, and the extracellular signal–regulated kinases 1 and 2. Some studies also show that part of apelin–APJ signaling is Gt-dependent. Apelin induces an inotropic response in cardiomyocytes by increasing the amplitude of the [Ca] transients,1 a group of scaffold proteins that not only regulate receptor desensitization and internalization but also activate alternative G-protein–independent signaling pathways downstream of G-protein–coupled receptors. Recent studies have highlighted the sophistication of APJ signaling and the exposure of cardiomyocytes to stretch, for instance, biases APJ to β-arrestin recruitment rather than Gi activation. This turned out to be the case, and Kang et al found the 2 G-proteins most frequently linked to APJ signaling, that is, G and G, were not involved in the apelin–APJ-mediated activation of MEF-2, whereas G was involved. Furthermore, the activation of G by apelin–APJ signaling elicited the phosphorylation and nuclear export of class II histone deacetylases (HDACs) in cultured endothelial cells. These in vitro observations were confirmed in vivo because Apj−/− embryos show increased endothelial nuclear accumulation of HDAC4 and HDAC5. How exactly G activation by APJ causes HDAC phosphorylation is unclear. Class II HDACs are generally phosphorylated by protein kinase D or the Ca/calmodulin-dependent kinase II, but there are only few accounts of G, activation and no previous reports of G,–dependent regulation of HDACs.

One currently unanswered question is the role of the agonist apelin in the newly described APJ signaling pathway. In endothelial cells that endogenously express APJ, the G or HDAC4 or HDAC5/MEF pathway could be enhanced with the addition of apelin or reduced by the small interfering RNA–mediated downregulation of APJ. However, Kang et al found the 2 G-proteins most frequently linked to APJ signaling, that is, G and G, were not involved in the apelin–APJ-mediated activation of MEF-2, whereas G was involved. Furthermore, the activation of G by apelin–APJ signaling elicited the phosphorylation and nuclear export of class II histone deacetylases (HDACs) in cultured endothelial cells. These in vitro observations were confirmed in vivo because Apj−/− embryos show increased endothelial nuclear accumulation of HDAC4 and HDAC5. How exactly G activation by APJ causes HDAC phosphorylation is unclear. Class II HDACs are generally phosphorylated by protein kinase D or the Ca/calmodulin-dependent kinase II, but there are only few accounts of G, activation and no previous reports of G,–dependent regulation of HDACs.

One currently unanswered question is the role of the agonist apelin in the newly described APJ signaling pathway. In endothelial cells that endogenously express APJ, the G or HDAC4 or HDAC5/MEF pathway could be enhanced with the addition of apelin or reduced by the small interfering RNA–mediated downregulation of APJ. However, Kang et al found the 2 G-proteins most frequently linked to APJ signaling, that is, G and G, were not involved in the apelin–APJ-mediated activation of MEF-2, whereas G was involved. Furthermore, the activation of G by apelin–APJ signaling elicited the phosphorylation and nuclear export of class II histone deacetylases (HDACs) in cultured endothelial cells. These in vitro observations were confirmed in vivo because Apj−/− embryos show increased endothelial nuclear accumulation of HDAC4 and HDAC5. How exactly G activation by APJ causes HDAC phosphorylation is unclear. Class II HDACs are generally phosphorylated by protein kinase D or the Ca/calmodulin-dependent kinase II, but there are only few accounts of G, activation and no previous reports of G,–dependent regulation of HDACs.

One currently unanswered question is the role of the agonist apelin in the newly described APJ signaling pathway. In endothelial cells that endogenously express APJ, the G or HDAC4 or HDAC5/MEF pathway could be enhanced with the addition of apelin or reduced by the small interfering RNA–mediated downregulation of APJ. However, Kang et al found the 2 G-proteins most frequently linked to APJ signaling, that is, G and G, were not involved in the apelin–APJ-mediated activation of MEF-2, whereas G was involved. Furthermore, the activation of G by apelin–APJ signaling elicited the phosphorylation and nuclear export of class II histone deacetylases (HDACs) in cultured endothelial cells. These in vitro observations were confirmed in vivo because Apj−/− embryos show increased endothelial nuclear accumulation of HDAC4 and HDAC5. How exactly G activation by APJ causes HDAC phosphorylation is unclear. Class II HDACs are generally phosphorylated by protein kinase D or the Ca/calmodulin-dependent kinase II, but there are only few accounts of G, activation and no previous reports of G,–dependent regulation of HDACs.
overexpression of APJ alone was sufficient to activate this pathway in COS7 or human endothelial cells and the dual overexpression of APJ and apelin failed to enhance the response. Such findings may imply that either APJ shows intrinsic activity or sufficient ligand is produced by the cells and present in the culture medium to induce significant APJ signaling. At least in vivo, apelin is mainly expressed by endothelial cells, making the latter a plausible option. There is, however, at least circumstantial evidence for the existence of apelin-independent APJ signaling because the phenotype of apelin-deficient (apln−/−) mice is distinctly different from that of Apj−/− mice. In contrast to the Apj−/− mice, apln−/− mice on the same genetic background are fully viable and do not show any developmental defects. Furthermore, although Apj−/− mice are protected from pressure overload–induced heart failure, 6 apln−/− mice show accelerated cardiac failure. 6 This discrepancy has been attributed to stretch-induced β-arrestin recruitment to APJ leading to prohypertrophic gene expression that can be overcome by apelin. 7 At present, it is not known whether endothelial APJ signaling also interferes with mechanotransduction, but the exposure of endocardial cells to fluid shear stress is vital in the early stages of cardiac development and drives the expression of KLF2 16,20 that also depends, at least in part, on APJ. 14

Given the predominant endothelial and endocardial expression of APJ, Kang et al 14 focused their attention on endothelial cell signaling. APJ expression, however, is not restricted to these cells and an important remaining question is how other cell types in the developing heart are affected by APJ deficiency. Certainly, the signaling defects found in cultured APJ-deficient endothelial cells could be confirmed in the Apj−/− embryos and deletion of KLF2, which in embryonic development is selectively expressed in endocardial cells, 21 causes a highly similar phenotype. 16 On the contrary, the importance of apelin–APJ signaling in adult cardiomyocytes is well-documented and both in vivo and in vitro models have shown that APJ is also important in driving cardiomyocyte differentiation of progenitor cells, particularly for correct expression of proteins building the contractile apparatus, 12,13,22,23 making it highly probable that APJ deficiency affects more than endothelial signaling even during embryonic development. The cell type–specific Apj−/− mice that currently are being generated should shed more light on these issues. 14

In summary, Kang et al 14 add another layer of complexity to APJ signaling by describing a novel APJ signaling route in endothelial cells through Gα13, leading to phosphorylation of class II HDACs and subsequent activation of MEF-2α/c–dependent transcription. The described developmental defects of variable severity provide more insight into the redundancy in signaling pathways contributing to congenital heart defects. However, they open our eyes to a completely novel signaling pathway downstream of APJ that should be taken into account when considering the therapeutic potential of apelin in the therapy of heart failure. 24

**Sources of Funding**

Studies performed in the author’s own laboratory were supported by the Deutsche Forschungsgemeinschaft (SFB 834/A4 and Exzellenzcluster 147 Cardio-Pulmonary System) to LF.

**Disclosures**

None.

**References**

11. Charo DN, Ho M, Fajardo G, Kawanami K, Kunod RK, Sheikh AY, Finsterbach TP, Lepser NJ, Ernst KV, Chen MM, Ho YD, Chu HI, Bernstein D, Ashley EA, Quertermous T. Endogenous regulation of...


Key Words: apelin receptor APJ mouse © cardiovascular development © Grt13 © GTP-binding proteins © MEF2A and MEF2C
A Novel APJ Signaling Cascade That Regulates Cardiovascular Development
Annemarieke E. Loot and Ingrid Fleming

Circ Res. 2013;113:4-6
doi: 10.1161/CIRCRESAHA.113.301632

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/113/1/4

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/